ERENUMAB
Information current as at: 1 March 2026
The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.
Submission Details
- Brand name:
-
- Aimovig®
- Pharmaceutical company:
- NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED
- Condition/indication:
(therapeutic use) -
- Chronic migraine
- PBAC Submission type:
- New PBS listing (Standard Re-entry Pathway)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – November 2024
- Related medicines:
Progress Details
-
Submission received for: - November 2024 PBAC meeting
-
Opportunity for consumer comment: - Open 31/07/2024 and close 25/09/2024 (see PBS Website)
-
PBAC meeting: - Held on 06/11/2024
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a932
Page last updated: 31 October 2025